BioSpace News Archive

Applied UV, Inc. announces, that its wholly owned subsidiary, SteriLumen has been notified that its European Distribution Partner, Cellarius has placed a substantial order.

Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol ® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company’s ongoing TransportNPC™ study evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC).

Day One Biopharmaceuticals, Inc. announced the closing on June 17, 2022 of its previously announced upsized underwritten public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,500,000 additional shares, at a public offering price of $15.00 per share.

Mr. Horvath will lead the commercialization of POINT’s pipeline. He brings over a decade of experience in pharmaceutical commercialization, most recently as the VP and Head of Prostate Cancer Radioligand Therapy Franchise at Advanced Accelerator Applications.

AIM ImmunoTech Inc. announced it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot R&D facility at the New Jersey Bioscience Center.

Linden Capital Partners (“Linden”), a Chicago -based private equity firm focused exclusively on the healthcare industry, today announced that it has signed a definitive agreement to make a majority investment in Aspirion (the “Company”), a leader in technology-enabled healthcare revenue cycle management (“RCM”).

MedX Health Corp. (“ MedX ” or the “ Company ”) ( TSXV: MDX ), a global leader in teledermatology, is pleased to announce that it has received final Acceptance from the TSX Venture Exchange in respect of the Closing of the placement of Series II Convertible Notes that took place on March 21, 2022, and which comprised issuance of 20 Series II Convertible Notes, and raised a total of $1 Million.

CosmosID® today announced a partnership for long-term support for Locus’ clinical trial initiatives.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced it is set to join the broad-market Russell 3000® Index as well as the Russell 2000® and Russell Microcap® Indexes.

Echosens Presents Symposium & Democenter at EASL International Liver Congress™ 2022: FibroScan ® Solutions Bringing New Guidelines to Life, New FibroScan GO Demonstrations.